Bennett Selby Investments LP Boosts Stock Position in Novo Nordisk A/S (NYSE:NVO)

Bennett Selby Investments LP lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 59.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 44,876 shares of the company’s stock after purchasing an additional 16,651 shares during the period. Novo Nordisk A/S accounts for approximately 1.2% of Bennett Selby Investments LP’s portfolio, making the stock its 19th largest position. Bennett Selby Investments LP’s holdings in Novo Nordisk A/S were worth $3,116,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Bangor Savings Bank lifted its position in Novo Nordisk A/S by 1.5% during the first quarter. Bangor Savings Bank now owns 16,980 shares of the company’s stock valued at $1,179,000 after buying an additional 243 shares during the period. Bank of New Hampshire increased its stake in shares of Novo Nordisk A/S by 11.8% in the 1st quarter. Bank of New Hampshire now owns 16,143 shares of the company’s stock worth $1,121,000 after acquiring an additional 1,699 shares in the last quarter. Miracle Mile Advisors LLC purchased a new position in Novo Nordisk A/S during the 1st quarter valued at about $278,000. Sivia Capital Partners LLC boosted its stake in Novo Nordisk A/S by 9.9% during the first quarter. Sivia Capital Partners LLC now owns 8,733 shares of the company’s stock worth $606,000 after acquiring an additional 784 shares in the last quarter. Finally, Princeton Global Asset Management LLC grew its holdings in Novo Nordisk A/S by 52.8% in the first quarter. Princeton Global Asset Management LLC now owns 4,250 shares of the company’s stock worth $295,000 after purchasing an additional 1,469 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Performance

NVO stock opened at $74.70 on Friday. The company has a market cap of $335.22 billion, a P/E ratio of 22.71, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock’s fifty day moving average price is $65.87 and its 200-day moving average price is $80.54.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on NVO shares. BNP Paribas started coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an “underperform” rating for the company. Guggenheim lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Dbs Bank lowered shares of Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. Finally, Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Friday. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $128.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.